Clinical, behavioral and biomarker predictors of PCSK9 levels in HIV-infected patients naïve of statin therapy: A cross-sectional analysis from the Swiss HIV cohort

摘要: Abstract Background and aims Better characterization of Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) profile is currently needed to tailor appropriate lipid-lowering strategies in HIV patients. Methods HIV-infected individuals aged ≥ 40 years naive statin therapy included the Swiss cohort study were screened for PCSK9 levels with a routine blood sample collection 2014 at Geneva University Hospitals. An exploratory linear regression model was built including clinical (age, sex, ethnicity, cardiovascular risk factors, body mass index, low CD4 defined as ≤200 cells/μl, leucocytes, lymphocytes, platelet, antiretroviral therapy), behavioral (tobacco marijuana smoking, alcohol use physical activity) biomarker (CRP, TNF-α, IL-8, Il-10 MCP-1) investigate association continuous levels. Results We studied 239 who met inclusion criteria available mean age 49 years. 35 subjects (14.6%) reported consumption, whom 20 (57.1%) daily consumption 15 (6.3%) occasional use. correlated low-density lipoprotein-cholesterol (LDL-C). Our identified (p=0.023) values (p=0.020) significantly associated factors higher No found Framingham score. Patients had dose-response effect (p Conclusions In treatment, are independently clinically relevant confounding factors.